Return on equity (ROE) is the profit a company earns for every dollar of shareholder money invested in it, shown as a percentage. It is net income divided by shareholder equity, and the table shows both amounts: the profit earned and the equity it was earned on. A higher ROE means more profit per dollar of equity, but ROE also rises when equity shrinks through buybacks, dividends or losses, and it has no meaning for a company with negative equity. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.
Trevi Therapeutics, Inc. roe for the quarter ending 2026-06-30 was -15.90%, a change of 7.93% year-over-year.
Trevi Therapeutics, Inc. roe for the quarter ending 2026-03-31 was -26.50%, a change of 21.11% year-over-year.
Trevi Therapeutics, Inc. roe for the quarter ending 2025-12-31 was -23.33%, a change of 24.75% year-over-year.
Trevi Therapeutics, Inc. roe for the quarter ending 2025-09-30 was -24.16%, a change of 50.99% year-over-year.
Trevi Therapeutics, Inc. roe for fiscal 2025 was -23.33%, a change of 24.75% from fiscal 2024.
Trevi Therapeutics, Inc. roe for fiscal 2024 was -48.08%, a change of -12.87% from fiscal 2023.
Trevi Therapeutics, Inc. roe for fiscal 2023 was -35.21%, a change of -8.08% from fiscal 2022.
Trevi Therapeutics, Inc. roe for fiscal 2022 was -27.13%, a change of 171.64% from fiscal 2021.